hujpharm

Hacettepe University Journal of the Faculty of Pharmacy

2458-8806

Hacettepe University

10.52794/hujpharm.1572311

Pharmaceutical Delivery Technologies

İlaç Dağıtım Teknolojileri

Industry-Patient-Friendly Tadalafil Oral Spray: Statistical Development, Functionality and In-Vivo Taste Assessment

https://orcid.org/0000-0002-2159-7665

Rana

Hardik

Anand Pharmacy College, Anand -388001, Gujarat, India

https://orcid.org/0000-0001-6332-7703

Gandhi

Vaishali

https://orcid.org/0000-0002-2011-1555

Gandhi

Tejal

03 01 2025

45 1 43 56 10 23 2024 02 25 2025

1981

Hacettepe University Journal of the Faculty of Pharmacy

The current work aimed to design a new patient-friendly Tadalafil (TDL) oral spray for management of erectile dysfunction employing concept of advanced data mining and analytical tools. An inclusion complex of TDL: Dexolve®, was formulated and characterized for its physicochemical properties. Phase solubility study suggested a 1:1 ratio of TDL: Dexolve® showed higher solubility. FTIR, DSC, and XRD studies confirmed the partial alteration of crystalline to amorphous. The complex assessed in-vivo for taste masking inculcating the BriefAccess Taste Aversion (BATA) model, indicated the taste masking of TDL. The complex was incorporated into spray formulation using water: ethanol, Vitamin D and HPMC E5. MLRA and ANOVA depicted the crucial correlation between amount of ethanol and HPMC E5 with spray pattern and % TDL release. The results of characterization suggested that it covered the maximum area of the oral cavity, indicated uniform distribution and more absorption. The design batches were evaluated for varied oral spray-related parameters and stability studies. The formulation was found stable and released TDL immediately. Dexolve® was found to be a promising multifunctional excipient. The oral spray prepared was environmentally friendly as it is propellant-free. The newer stable and immediateacting spray improves release of TDL and is patient-friendly.

Tadalafil BATA model Oral spray Vitamin D Dexolve®

1. Grice PT, Liu J, Gabrielson AT, Pearce I, Bivalacqua TJ, Modgil V. Drug delivery options and therapeutic advances in the management of erectile dysfunction. Expert Opin Drug Deliv. 2020;17(9):1259–68. 10.1080/17425247.2020.1782383

2. Goldstein I, Goren A, Li VW, Tang WY, Hassan TA. Epidemiology Update of Erectile Dysfunction in Eight Countries with High Burden. Sex Med Rev. 2020;8(1):48–58. 10.1016/j. sxmr.2019.06.008

3. Kaabi Y. Comprehensive analysis of global research on overactive bladder: A scientometric approach. Int J Gen Med. 2023;16:5729–41. https://doi.org/10.3389/ fsurg.2022.1078052

4. Rezali MS, Mohamad Anuar MF, Abd Razak MA, Chong ZL, Shaharudin AB, Kassim MSA, et al. Prevalence and associated factors of moderate to severe erectile dysfunction among adult men in Malaysia. Sci Rep. 2023;13(1):1–10. 10.1038/ s41598-023-48778-y

5. Shiferaw WS, Akalu TY, Aynalem YA. Prevalence of Erectile Dysfunction in Patients with Diabetes Mellitus and Its Association with Body Mass Index and Glycated Hemoglobin in Africa: A Systematic Review and Meta-Analysis. Int J Endocrinol. 2020;2020. 10.1155/2020/5148370

6. Pang K, Pan D, Xu H, Ma Y, Wang J, Xu P, et al. Advances in physical diagnosis and treatment of male erectile dysfunction. Front Physiol. 2023;13(January 2023):1–14. 10.3389/fphys.2022.1096741

7. Sooriyamoorthy T. Erectile dysfunction. J Med Liban. 2004;52(4):213–6.

8. Ong YN, Tan YG, Handayani D, How CH. Erectile dysfunction: Assessment and management in primary care. Singapore Med J. 2024;65(3):190–4. 10.4103/singaporemedj.SMJ-2022- 101

9. El-Osta A, Kerr G, Alaa A, El Asmar ML, Karki M, Webber I, et al. Investigating self-reported efficacy of lifestyle medicine approaches to tackle erectile dysfunction: a cross-sectional eSurvey based study. BMC Urol. 2023;23(1):1–12. 10.1186/ s12894-023-01180-2

10. Yu X, Tian T, Han W, Zhang X, Wang Q. Attitudes and preferences towards erectile dysfunction treatment among men with fertility needs: insights from a clinical study. Sci Rep. 2024;14(1):22256. 10.1038/s41598-024-73328-5

11. Gurbel PA, Jeong YH, Tantry US. Phosphodiesterase inhibitors [Internet]. Padda I, Tripp J, editors. NCBI Bookshelf. Pubmed; 2021. 1–17 p. 10.1016/B978-0-12-813456-6.00054-0

12. Zhao ZL, Peng D, Liu X, Li XC, Lan LJ, Wu XH, et al. Formulation and characterization of tadalafil-loaded orodispersible films with enhanced dissolution rate and membrane permeability. J Drug Deliv Sci Technol. 2023;84(June):1–5. 10.1016/j.jddst.2023.104535

13. Mehanna MM, Mneimneh AT, Domiati S, Allam AN. Tadalafil- loaded limonene-based orodispersible tablets: Formulation, in vitro characterization and in vivo appraisal of gastroprotective activity. Int J Nanomedicine. 2020;15:10099–112.10.2147/IJN.S288552

14. Shukla SK, Chan A, Parvathaneni V, Kanabar DD, Patel K, Ayehunie S, et al. Enhanced solubility, stability, permeation and anti-cancer efficacy of Celastrol-β-cyclodextrin inclusion complex. J Mol Liq. 2020;318:113936. 10.1016/j.molliq.2020.113936

15. Sid D, Baitiche M, Elbahri Z, Djerboua F, Boutahala M, Bouaziz Z, et al. Solubility enhancement of mefenamic acid by inclusion complex with β-cyclodextrin: in silico modelling, formulation, characterisation, and in vitro studies. J Enzyme Inhib Med Chem. 2021;36(1):605–17. 10.1080/14756366.2020.1869225

16. Alshehri S, Imam SS, Altamimi MA, Hussain A, Shakeel F, Alshehri A. Stimulatory Effects of Soluplus ® on Flufenamic Acid β -Cyclodextrin Supramolecular Complex : Physicochemical Characterization and Pre-clinical Anti-in fl ammatory Assessment. AAPS PharmSciTech. 2020;21(5):145–57.

17. Wang H, Wang S, Zhu H, Wang S, Xing J. Inclusion complexes of lycopene and β-cyclodextrin: Preparation, characterization, stability and antioxidant activity. Antioxidants. 2019;8:314. 10.3390/antiox8080314

18. Han J, Tang M, Yang Y, Sun W, Yue Z, Zhang Y, et al. Amorphous solid dispersions: Stability mechanism, design strategy and key production technique of hot melt extrusion. Int J Pharm. 2023;646(November):1–8. 10.1016/j.ijpharm.2023.123490

19. Bakirova R, Nukhuly A, Iskineyeva A, Fazylov S, Burkeyev M, Mustafayeva A, et al. Obtaining and Investigation of the β -Cyclodextrin Inclusion Complex with Vitamin D 3 Oil Solution. Hindawi Sci. 2020;2020. 10.1155/2020/6148939

20. Lopes MS, Catelani TA, Nascimento ALCS, Garcia JS, Trevisan MG. Ketoconazole: compatibility with pharmaceutical excipients using DSC and TG techniques. J Therm Anal Calorim. 2020;141(4):1371–8. 10.1007/s10973-019-09137-0

21. Muqtader Ahmed M, Fatima F, Abul Kalam M, Alshamsan A, Soliman GA, Shaikh AA, et al. Development of spray-dried amorphous solid dispersions of tadalafil using glycyrrhizin for enhanced dissolution and aphrodisiac activity in male rats. Saudi Pharm J. 2020;28(12):1817–26. 10.1016/j. jsps.2020.11.007

22. Rana H, Panchal M, Thakkar V, Gandhi T, Dholakia M. Investigating in-vitro functionality and in-vivo taste assessment of eco-friendly Tadalafil Pastilles. Heliyon. 2024;10(8):e29543. 10.1016/j.heliyon.2024.e29543

23. Mai NNS, Otsuka Y, Kawano Y, Hanawa T. Preparation and characterization of solid dispersions composed of curcumin, hydroxypropyl cellulose and/or sodium dodecyl sulfate by grinding with vibrational ball milling. Pharmaceuticals. 2020;13(11):1–15. 10.3390/ph13110383

24. Aminu N, Chan S-Y, Mumuni MA, Umar NM, Tanko N, Zauro SA, et al. Physicochemical compatibility studies of triclosan and flurbiprofen with excipients of pharmaceutical formulation using binary, ternary, and multi-combination approach. Futur J Pharm Sci. 2021;7(1). 10.1186/s43094-021-00302-7

25. Mondal S, Sirvi A, Jadhav K, Sangamwar AT. Supersaturating lipid-based solid dispersion of atazanavir provides enhanced solubilization and supersaturation in the digestive aqueous phase. Int J Pharm. 2023;638(May):1–10. 10.1016/j.ijpharm. 2023.122919

26. Cheung LC, Nguyen M, Tang E, von Ungern Sternberg BS, Salman S, Tuleu C, et al. Taste evaluation of a novel midazolam tablet for pediatric patients: In vitro drug dissolution, in vivo animal taste aversion and clinical taste perception profiles. Int J Pharm. 2018;535(1–2):194–200. 10.1016/j.ijpharm. 2017.10.060

27. Clapham D, Belissa E, Inghelbrecht S, Pensé-Lhéritier AM, Ruiz F, Sheehan L, et al. A Guide to Best Practice in Sensory Analysis of Pharmaceutical Formulations. Pharmaceutics. 2023;15(9). 10.3390/pharmaceutics15092319

28. Sugibayashi K, Yamamoto N, Itakura S, Okada A, Hijikuro I, Todo H. Development of spray formulations applied to the oral mucosa using non-lamellar liquid crystal-forming lipids. Chem Pharm Bull. 2020;68(11):1025–33. 10.1248/cpb.c20- 00333

29. Sipos B, Katona G, Csóka I. A systematic, knowledge spacebased proposal on quality by design-driven polymeric micelle development. Pharmaceutics. 2021;13(5). 10.3390/pharmaceutics13050702

30. Dhote V, Dangi U, Mandloi AS, Soni M, Shukla DN, Kawadkar M, et al. Preferential cyclooxygenase inhibition by Jasminum sambac: A possible relationship with potent anti-arthritic activity. J Tradit Complement Med. 2021;11(3):217–27. 10.1016/j.jtcme.2020.04.002

31. de Barros C, Aranha N, Severino P, Souto EB, Zielińska A, Lopes A, et al. Quality by design approach for the development of liposome carrying ghrelin for intranasal administration. Pharmaceutics. 2021;13(5). 10.3390/pharmaceutics13050686

32. Gunda RK, Manchineni PR. Statistical design and optimization of sustained release formulations of pravastatin. Turkish J Pharm Sci. 2020;17(2):221–7. 10.4274/tjps.galenos. 2019.70048

33. Rana H, Dholakia M, Gohel M, Omri A, Thakkar V, Gandhi T. Demonstration of Advanced Data Mining Tools for Optimization of Pellets Employing Modified Extrusion-pelletization Technique. Curr Drug ther. 2020;16(2):154–69. 10.2174/1574 885515999201217155123

34. Umar AK, Butarbutar M, Sriwidodo S, Wathoni N. Filmforming sprays for topical drug delivery. Drug Des Devel Ther. 2020;14:2909–25. 10.2147/DDDT.S256666

35. Ruwaida W. Abdo, Najlaa Saadi NIH and YAS. Evaluation of Pharmaceutical Aerosols. In: Drug Delivery Systems. Elsevier; 2020. p. 580–614. 10.1016/B978-0-12-814487-9.00012-0579

36. Aravindhanthan V. Sublingual spray: a new technology oriented formulation with multiple benefits. Int J Res Pharm Sci. 2019;10(4):2875–85. 10.1144/gsl.mem.1999.018.01.02

37. Shah M, Patel D. Development and characterization of tadalafil solid dispersion using skimmed milk for improved the solubility and dissolution release profile. Res J Pharm Technol. 2020;13(12):6212–7. 10.5958/0974-360X.2020.01083.5

38. Basu S, Holbrook LT, Kudlaty K, Fasanmade O, Wu J, Burke A, et al. Numerical evaluation of spray position for improved nasal drug delivery. Sci Rep. 2020;10(1):1–18. 10.1038/ s41598-020-66716-0

39. Peng Y, Via B. The effect of cellulose nanocrystal suspension treatment on suspension viscosity and casted film property. Polymers (Basel). 2021;13(13). 10.3390/polym13132168

40. Bartos C, Szabó-Révész P, Horváth T, Varga P, Ambrus R. Comparison of modern in vitro permeability methods with the aim of investigation nasal dosage forms. Pharmaceutics. 2021;13(6). 10.3390/pharmaceutics13060846

41. ICH. ICH harmonised tripartite guideline stability testing of New drug substances and products Q1A (R2). Stability Testing of New Drug Substances and Products 2003 p. 24.

42. Lin SY. Current and potential applications of simultaneous DSC-FTIR microspectroscopy for pharmaceutical analysis. J Food Drug Anal. 2021;29(2):182–202. 10.38212/2224- 6614.3345

43. Shan X, Moghul MA, Williams AC, Khutoryanskiy V V. Mutual effects of hydrogen bonding and polymer hydrophobicity on ibuprofen crystal inhibition in solid dispersions with poly(N-vinyl pyrrolidone) and poly(2-oxazolines). Pharmaceutics. 2021;13(5).